4.5 Article

LIM-domain-only proteins: multifunctional nuclear transcription coregulators that interacts with diverse proteins

期刊

MOLECULAR BIOLOGY REPORTS
卷 41, 期 2, 页码 1067-1073

出版社

SPRINGER
DOI: 10.1007/s11033-013-2952-1

关键词

LIM domain; LMO; Gene transcription; LDB1; Protein-protein interaction

资金

  1. National Nature Science Foundation of China [81001178]

向作者/读者索取更多资源

The LIM-only subclass of LIM proteins is a family of nuclear transcription co-regulators that are characterized by the exclusive presence of two tandem LIM domains and no other functional domains. To date, four LIM-domain-only (LMO) proteins (LMO1-LMO4) have been identified. They regulate gene transcription by functioning as linker or scaffolding proteins with a remarkable potential to mediate protein-protein interactions. These proteins play important roles in cell fate determination, cell growth and differentiation, tissues patterning, and organ development. In this review, we briefly described the functions of LMO proteins in the organ development and diseases. We also summarized the interaction proteins of each LMO family member, which may contribute to elucidating the functions of these mysterious and important linker proteins.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Cell Biology

Long non-coding RNA linc00921 suppresses tumorigenesis and epithelial-to-mesenchymal transition of triple-negative breast cancer via targeting miR-9-5p/LZTS2 axis

Jie Zhang, Lina Zhang, Jianlong Wang, Jing Zhao, Xuelian Zhao, Chunli Zhang, Peng Han, Cuizhi Geng

Summary: This study found that Linc00921 upregulates LZTS2 by sponging miR-9-5p, suppressing tumorigenesis and epithelial-to-mesenchymal transition (EMT) in TNBC.

HUMAN CELL (2022)

Article Biotechnology & Applied Microbiology

CircRNA ZNF609 promotes the growth and metastasis of thyroid cancer in vivo and in vitro by downregulating miR-514a-5p

Ping Shi, Yan Liu, Dongqiang Yang, Yanzhao Wu, Lan Zhang, Shanghua Jing, Huijing Shi, Cuizhi Geng

Summary: The study revealed that circ-ZNF609 was highly expressed while miR-514a-5p was downregulated in TC cells. Knockdown of circ-ZNF609 inhibited malignant behaviors of TPC-1 and IHH-4 cells, and circ-ZNF609 sponged miR-514a-5p to impact TC cell behaviors. Furthermore, silencing of circ-ZNF609 significantly repressed TC tumorigenesis in vivo, indicating its important role in TC development and metastasis.

BIOENGINEERED (2022)

Article Biotechnology & Applied Microbiology

MicroRNA-409 regulates the proliferation and invasion of breast cancer cell lines by targeting special AT-rich sequence-binding protein 1 (SATB1)

Zhi Chen, Mei-Xiang Sang, Cui-Zhi Geng, Hui-Qun Jia

Summary: This study determines the role of miR-409 in breast cancer by targeting SATB1 and highlights its potential as a therapeutic target for the treatment of breast cancer.

BIOENGINEERED (2022)

Article Oncology

Nomogram for Early Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Combining Both Clinicopathological and Imaging Indicators

Haoqi Wang, Yuyang Lu, Yilun Li, Sainan Li, Xi Zhang, Cuizhi Geng

Summary: A nomogram was constructed for early prediction of pathological complete response (pCR) in breast cancer patients after neoadjuvant chemotherapy. The nomogram showed excellent discrimination ability and diagnostic value in predicting pCR, and it may provide guidance for clinicians in adjusting treatment programs.

CURRENT PROBLEMS IN CANCER (2022)

Article Oncology

Proxalutamide in patients with AR-positive metastatic breast cancer: Results from an open-label multicentre phase Ib study and biomarker analysis

Hanfang Jiang, Quchang Ouyang, Yongmei Yin, Zhongshen Tong, Kunwei Shen, Zhongyu Yuan, Cuizhi Geng, Yaxin Liu, Guohong Song, Ran Ran, Wei Li, Qing Qu, Meiyu Wang, Luping Meng, Youzhi Tong, Huiping Li

Summary: The study evaluated the efficacy and safety of a novel non-steroidal androgen receptor antagonist, Proxalutamide, in patients with AR-positive metastatic breast cancer. The results showed promising anti-tumor activity and tolerability of Proxalutamide, supporting further investigation of this drug.

EUROPEAN JOURNAL OF CANCER (2022)

Article Oncology

Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4

Binghe Xu, Xichun Hu, Wei Li, Tao Sun, Kunwei Shen, Shusen Wang, Ying Cheng, Qingyuan Zhang, Shude Cui, Zhongsheng Tong, Cuizhi Geng, Erwei Song, Chiun-Sheng Huang, Virote Sriuranpong, Roger K. C. Ngan, Yee H. Chia, Xinwei Wang, Huadong Zhao

Summary: The PALOMA-4 study demonstrates the efficacy and safety of first-line palbociclib plus letrozole in postmenopausal Asian women with ER+/HER2- ABC. No new safety concerns were identified for the combination therapy.

EUROPEAN JOURNAL OF CANCER (2022)

Article Oncology

circRNF10 Regulates Tumorigenic Properties and Natural Killer Cell-Mediated Cytotoxicity against Breast Cancer through the miR-934/PTEN/PI3k-Akt Axis

Fei Liu, Yang Sang, Yang Zheng, Lina Gu, Lingjiao Meng, Ziyi Li, Yuyang Dong, Zishuan Wei, Cuizhi Geng, Meixiang Sang

Summary: This study reveals that circRNF10 acts as an anti-oncogene in breast cancer by serving as a sponge for miR-934 and suppressing the PI3K/AKT/MICA pathway. Increased expression of circRNF10 inhibits proliferation, invasion, and migration of breast cancer cells and enhances the cytotoxicity of NK cells against breast cancer cells. The findings provide novel insights into the molecular mechanism and function of circRNAs in breast cancer.

CANCERS (2022)

Article Oncology

Role of PAX2 in breast cancer verified by bioinformatics analysis and in vitro validation

Shan Yang, Wei Gao, Haoqi Wang, Xi Zhang, Yunzhe Mi, Yawen Ding, Cuizhi Geng, Jie Zhang, Meng Cheng, Sainan Li

Summary: By analyzing data from breast cancer patients, it was found that PAX2 is highly expressed in breast cancer and is associated with tumor size and lymph node metastasis. PAX2 deficiency can promote the growth, migration, and invasion of breast cancer cells.

ANNALS OF TRANSLATIONAL MEDICINE (2023)

Article Oncology

Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Pin Zhang, Qingyuan Zhang, Zhongsheng Tong, Tao Sun, Wei Li, Quchang Ouyang, Xichun Hu, Ying Cheng, Min Yan, Yueyin Pan, Yuee Teng, Xi Yan, Ying Wang, Weimin Xie, Xiaohua Zeng, Xiaojia Wang, Changlu Hu, Cuizhi Geng, Hongwei Zhang, Wenxin Li, Xinhong Wu, Jincai Zhong, Jingwei Xu, Yanxia Shi, Wenhua Wei, Nayima Bayaxi, Xiaoyu Zhu, Binghe Xu

Summary: This study evaluated the efficacy and safety of adding CDK4/6 inhibitor dalpiciclib to letrozole or anastrozole as first-line treatment for patients with hormone receptor-positive, HER2-negative advanced breast cancer who had not received previous systemic therapy. The results showed that dalpiciclib plus endocrine therapy significantly prolonged progression-free survival compared to placebo plus endocrine therapy, indicating it as a potential standard treatment option for this patient population.

LANCET ONCOLOGY (2023)

Article Oncology

An Analysis of Clinical and Pathologic Features, RecurIndex Genomic Profiles, and Survival Outcomes in HER2-Low Breast Cancer

Tianli Hui, Sainan Li, Huimin Wang, Xuejiao Ma, Furong Du, Wei Gao, Shan Yang, Meixiang Sang, Ziyi Li, Ran Ding, Yueping Liu, Cuizhi Geng

Summary: In this study, data from early-stage breast cancer patients who had undergone RecurIndex testing was analyzed to better understand the clinical and genetic characteristics of HER2-low tumors. The results showed that HER2-low tumors had significantly higher rates of hormone receptor positivity, luminal-type characteristics, and low Ki67 levels compared to HER2-negative tumors. Furthermore, within the HER2-negative disease, HER2-low tumors with hormone receptor positivity showed elevated expression levels of ESR1, NFATC2IP, PTI1, ERBB2, and OBSL1. Survival analysis revealed that lower HER2 expression was associated with improved relapse-free survival in hormone receptor-positive tumors. This study highlights the unique features of HER2-low tumors and suggests that hormone receptor status may influence the prognosis of patients with HER2-low expression.

ONCOLOGIST (2023)

Article Medicine, General & Internal

Trends in Disparities and Transitions of Treatment in Patients With Early Breast Cancer in China and the US, 2011 to 2021

Jianbin Li, Jifang Zhou, Haibo Wang, Zhenzhen Liu, Zhimin Fan, Yinhua Liu, Cuizhi Geng, Yue Xiao, Zefei Jiang

Summary: This study compared the treatment trends and disparities among women with early breast cancer in China and the US. The findings showed that Chinese patients were younger and had more late-stage and aggressive cancer subtypes. After 2017, a higher proportion of ERBB2-positive patients in China received trastuzumab-based therapy compared to the US. These findings suggest a narrowing disparity in early breast cancer treatment between China and the US from 2011 to 2021.

JAMA NETWORK OPEN (2023)

Article Pharmacology & Pharmacy

GLIS Family Zinc Finger 3 Promotes Triple-Negative Breast Cancer Progression by Inducing Cell Proliferation, Migration and Invasion, and Activating the NF-KB Signaling Pathway

Chenhao Li, Cuizhi Geng

Summary: GLIS3 is highly expressed in TNBC and promotes tumor activities by activating the NF-KB signaling pathway, indicating its crucial role in TNBC progression.

BIOLOGICAL & PHARMACEUTICAL BULLETIN (2023)

Article Oncology

Methylation detection of circulating tumor cell miR-486-5p/miR-34c-5p in the progression of colorectal cancer

Guolei Li, Xuhua Hu, Guiying Wang, Cuizhi Geng

Summary: This study investigated the expression and methylation levels of miR-486-5p/miR-34c-5p and its mechanism of action in colorectal cancer (CRC) using clinical data and tissue detection. The results showed low expression and high methylation levels of miR-486-5p/miR-34c-5p in circulating tumor cells (CTCs), as well as in tumor cells and tissues. Demethylation and overexpression of miR-486-5p/miR-34c-5p effectively inhibited proliferation, invasion, and migration of CRC cells, and promoted tumor apoptosis. These findings suggest that miR-486-5p/miR-34c-5p could be potential therapeutic targets for CRC.

CLINICAL & TRANSLATIONAL ONCOLOGY (2023)

Article Oncology

Long non-coding RNA GHET1 promotes thyroid cancer cell proliferation and invasion

Yan Liu, Ping Shi, Hao Fang, Zhen Zhao, Fei Yang, Jie Zhang, Shanghua Jing, Cuizhi Geng

Summary: The study found that LncRNA GHET1 is significantly upregulated in TC tissues and cell lines, and is significantly associated with tumor invasion, gender, and lymph node metastasis in patients with thyroid cancer. Interference experiments on LncRNA GHET1 showed that silencing it in BCPAP cells can inhibit cell proliferation, invasion, and migration, while overexpression in TPC cells promotes these cell processes.

TRANSLATIONAL CANCER RESEARCH (2021)

Article Oncology

Recognition of the organ-specific mutations in metastatic breast cancer by circulating tumor cells isolated in vivo

Sainan Li, Shan Yang, Jiajie Shi, Yawen Ding, Wei Gao, Meng Cheng, Yuqiao Sun, Yanli Xie, Meixiang Sang, Hongxia Yang, Cuizhi Geng

Summary: The failure to treat and control the growth of metastases is the main cause of death in breast cancer (BC) patients. Capturing intact circulating tumor cells (CTCs) allows for more accurate characterization of mutations and identification of suitable targeted therapies. Different metastasis sites contain specific high-frequency mutation genes, providing guidance for accurate gene therapy.

NEOPLASMA (2021)

暂无数据